Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Solid BiosciencesSLDB -2.37%34 Days Sales Outstanding is 0.00 as of Jun. 2026. GuruFocus rates SLDB with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 835 Biotechnology companies, Solid Biosciences ranks worse than 119760.36% on this metric.
The historical rank and industry rank for Solid Biosciences's Days Sales Outstanding or its related term are showing as below:
During the past 11 years, Solid Biosciences's highest Days Sales Outstanding was 4.96. The lowest was 2.95. And the median was 3.96.
SLDB's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 68.94 * Ranked among companies with meaningful Days Sales Outstanding only.
Solid Biosciences's Days Sales Outstanding
stayed the same
from Jun. 2025 (0.00) to Jun. 2026 (0.00).
Solid Biosciences (NAS:SLDB) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Solid Biosciences Days Sales Outstanding Related Terms
Solid Biosciences Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Solid Biosciences's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SLDB vs MNPR, DSGN, CLYM: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Solid Biosciences's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solid Biosciences Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Solid Biosciences's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Solid Biosciences's Days Sales Outstanding falls into.
Solid Biosciences Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solid Biosciences (SLDB) has a Days Sales Outstanding of 0.00 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Solid Biosciences and its competitors. Over the past decade, Solid Biosciences' Days Sales Outstanding has ranged from 2.95 to 4.96. According to the industry distribution chart, Solid Biosciences ranks #999999 out of 835 companies in the Biotechnology industry.
Is Solid Biosciences' Days Sales Outstanding too high?
Solid Biosciences' current Days Sales Outstanding is 0.00. Over the past 10 years, this metric has ranged from a low of 2.95 to a high of 4.96. Based on the distribution chart, Solid Biosciences ranks #999999 out of 835 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Solid Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Solid Biosciences' Days Sales Outstanding compare to MNPR and DSGN?
According to the Biotechnology industry distribution chart, Solid Biosciences ranks #999999 out of 835 companies for Days Sales Outstanding. This places Solid Biosciences in the lower half of its industry. The industry median Days Sales Outstanding is 68.94. Historically, Solid Biosciences' own Days Sales Outstanding has ranged from 2.95 to 4.96 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 835 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Solid Biosciences and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solid Biosciences's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solid Biosciences stock overvalued right now?
Solid Biosciences (SLDB) has a current Days Sales Outstanding of 0.00. The current Days Sales Outstanding is 0.00. Solid Biosciences' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Solid Biosciences (SLDB), the current Days Sales Outstanding is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
34GF Score
Get the complete analysis for SLDB
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLDB has been successfully added to your 
